From the above, it could be seen that the abnormal expression of ASNS, LAMP2, CAV1, DPP4 in triple-negative breast cancer and HELLS, TF, ZFP69B in breast cancer have not been experimentally verified, and these genes could exist as potential treatment biomarkers of TNBC. The gene discussed is ZFP69B; the disease is triple-negative breast carcinoma.